RLAY vs TYRA
RLAY: A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics. TYRA: Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly targeting FGFR-driven diseases.
Side-by-side fundamentals
| Metric | RLAY | TYRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.27 | $30.59 | |
| Market cap as of 2026-07-23 | $4.2B | $1.8B | |
| PEG as of 2026-07-23 | n/a | -0.44 | |
| Net margin as of 2026-07-23 | -1859.7% | n/a | |
| Operating margin as of 2026-07-23 | -2023.7% | n/a | |
| ROE as of 2026-07-23 | -43.9% | -42.7% | TYRA higher |
| ROA as of 2026-07-23 | -40.1% | -39.8% | TYRA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +39.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +123.2% | n/a | |
| Beta as of 2026-07-23 | 1.67 | 0.75 | |
| 1-year return as of 2026-07-22 close | +431.7% | +200.2% | RLAY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.